| Added by | pmartino |
|---|---|
| Group name | EquipePM |
| Item Type | Journal Article |
| Title | Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience |
| Creator | Liu et al. |
| Author | Yang Liu |
| Author | Yutaka Yonemura |
| Author | Edward A. Levine |
| Author | Olivier Glehen |
| Author | Diane Goere |
| Author | Dominique Elias |
| Author | David L. Morris |
| Author | Paul H. Sugarbaker |
| Author | Jean J. Tuech |
| Author | Peter Cashin |
| Author | John D. Spiliotis |
| Author | Ignace de Hingh |
| Author | Wim Ceelen |
| Author | Joel M. Baumgartner |
| Author | Pompiliu Piso |
| Author | Kanji Katayama |
| Author | Marcello Deraco |
| Author | Shigeki Kusamura |
| Author | Marc Pocard |
| Author | Sachio Fushita |
| Abstract | BACKGROUND: The multi-institutional registry in this study evaluated the outcome after cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases (PM) from small bowel adenocarcinoma (SBA). METHODS: A multi-institutional data registry including 152 patients with PM from SBA was established. The primary end point was overall survival (OS) after CRS plus HIPEC. RESULTS: Between 1989 and 2016, 152 patients from 21 institutions received a treatment of CRS plus HIPEC. The median follow-up period was 20 months (range 1-100 months). Of the 152 patients, 70 (46.1%) were women with a median age of 54 years. The median peritoneal cancer index (PCI) was 10 (mean 12; range 1-33). Completeness of cytoreduction (CCR) 0 or 1 was achieved for 134 patients (88.2%). After CRS and HIPEC, the median OS was 32 months (range 1-100 months), with survival rates of 83.2% at 1 year, 46.4% at 3 years, and 30.8% at 5 years. The median disease-free survival after CCR 0/1 was 14 months (range 1-100 months). The treatment-related mortality rate was 2%, and 29 patients (19.1%) experienced grades 3 or 4 operative complications. The period between detection of PM and CRS plus HIPEC was 6 months or less (P = 0.008), and multivariate analysis identified absence of lymph node metastasis (P = 0.037), well-differentiated tumor (P = 0.028), and PCI of 15 or lower (P = 0.003) as independently associated with improved OS. CONCLUSION: The combined treatment strategy of CRS plus HIPEC achieved prolonged survival for selected patients who had PM from SBA with acceptable morbidity and mortality. |
| Publication | Annals of Surgical Oncology |
| Volume | 25 |
| Issue | 5 |
| Pages | 1184-1192 |
| Date | May 2018 |
| Journal Abbr | Ann. Surg. Oncol. |
| Language | eng |
| DOI | 10.1245/s10434-018-6369-x |
| ISSN | 1534-4681 |
| Short Title | Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma |
| Library Catalog | PubMed |
| Call Number | IMPACT: 3.857 |
| Extra | PMID: 29484565 PMCID: PMC5891561 IMPACT: 3.857 |
| Tags | Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, clinic, Cytoreduction Surgical Procedures, Disease-Free Survival, Female, Humans, Hyperthermia, Induced, Intestinal Neoplasms, Intestine, Small, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Grading, Peritoneal Neoplasms, Postoperative Complications, Registries, Severity of Illness Index, Survival Rate |
| Date Added | 2019/02/19 - 08:59:40 |
| Date Modified | 2021/03/05 - 10:43:59 |
| Notes and Attachments | Full Text (Attachment) PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
